
|Videos|August 7, 2021
Evaluating risuteganib for dry eye disease treatment
Author(s)David Hutton, Alex Delaney-Gesing
Advertisement
Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island (Garden City, NY), discusses highlights from his presentation of trial results analyzing risuteganib as a potential treatment for dry eye disease.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
4
PainReform launches development plan for OcuRing-K, readies phase 2 trial
5















































.png)


